Abstract：【Objective】 To investigate the efficacy of rituximab combined with chemotherapy in patients with diffuse large B cell lymphoma (DLBCL). 【Methods】 According to different treatment regimens, 95 patients with DLBCL were divided into two groups. The observation group was treated with rituximab combined with chemotherapy (CHOP), while the control group was treated with chemotherapy alone. The short-term efficacy, adverse reactions and changes of lymphocyte subsets pre- and post- treatment were compared between the two groups. The 3-year survival rates of the two groups were also calculated. 【Results】 ①The short-term overall response rate of the observation group was 86% (43/50), which was significantly higher than that of the control group 62.22% (28/45) (P<0.05). ②There were no significant differences in levels of total T cells, CD4+, CD8+ or NK cells in the observation group before and after treatment (P>0.05), however, the level of B cells in the observation group after treatment was significantly lower than that in the control group (P<0.05). ③There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). ④During 1-year and 3-year follow-up, the 1-year progression-free survival rate (80%,40/50) and 1-year total survival rate (92%,46/50) of the observation group were significantly higher than those in the control group (57.78% and 75.56%, respectively) (P<0.05). The 3-year progression-free survival rate of the observation group was significantly higher than that of the control group (P<0.50), while there was no significant difference in 3-year total survival rate (P>0.05). 【Conclusion】 Compared to chemotherapy (CHOP) alone, rituximab combined with CHOP chemotherapy can significantly improve the short-term efficacy in patients with DLBCL, significantly improve the progression free survival rate, and, furthermore, does not increase the adverse reactions of chemotherapy. The regimen has little effect on T lymphocytes and NK cells though it significantly reduces B lymphocytes.
黄婧. 利妥昔单抗联合化疗治疗弥漫大B细胞淋巴瘤患者的疗效[J]. 医学临床研究, 2018, 35(12): 2346-2348.
HUANG Jing. Curative Effects of Rituximab Combined with Chemotherapy in the Treatment of Diffuse Large B Cell Lymphoma. JOURNAL OF CLINICAL RESEARCH, 2018, 35(12): 2346-2348.
[1] 李芬,陈琼,涂媛,等.弥漫大B细胞淋巴瘤临床病理特征及预后分析[J].医学临床研究,2016,33(8):1474-1476. [2] 冯继锋,吴剑秋,宋永平,等.利妥昔单抗联合化疗一线治疗初治弥漫大B细胞淋巴瘤的临床现状[J].中华血液学杂志,2014,35(4):309-313. [3] 张之南,沈悌.血液病诊断及疗效标准[M].北京:科学出版社,2007:131-132. [4] Cheson BD,Horning SJ,Coiffier B,et al.Report of an internationalwor-kshop to standardize response criteria for non-Hodgkin’s lymphomas:NCI Sp-onsored International Working Group[J].J Clin Oncol,1999,17(4) : 1244-1253. [5] 陈艳欣,郑晓云,刘庭波,等.利妥昔单抗联合CHOP与单用CHOP方案治疗初治弥漫大B细胞淋巴瘤疗效及安全性对比[J].临床血液学杂志,2015,28(5):760-763. [6] Uddin S,Hussain AR,Ahmed M,et al.Overexpression of FoxMl offers a pro-mising therapeutic target in diffuse large B-cell lymphoma[J].Haematologica,201-2,97(7):1092-1100. [7] 王晓雪,高然,于锦香,等.美罗华联合CHOP方案与单用CHOP方案治疗Ⅲ、Ⅳ期弥漫大B细胞性淋巴瘤的临床对比研究[J].中国医科大学学报,2012,41(4):373-376. [8] Pohlen M,Gerth HU,Liersch R.Efficacy and toxicity of a rituximab And methotrexate based regimen(GMALL B-ALL/NHL 2002 protocol) in Burkitt’s and primary mediastinal large Bcell lymphoma[J].Am J Hematol,2011,86(12):E6-1-64. [9] 陈思言,杨丽华,乔爱国,等.利妥昔单抗联合化疗治疗弥漫大B细胞淋巴瘤的临床疗效观察[J].西部医学,2015,27(10):1555-1557.
2018, Vol. 35 
